Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Prelude Therapeutics ( (PRLD) ) has provided an update.
On November 3, 2025, Prelude Therapeutics entered into an Exclusive Option Agreement with Incyte Corporation to potentially acquire Prelude’s JAK2V617F JH2 inhibitor program, aimed at treating myeloproliferative neoplasms (MPNs). The agreement provides Prelude with $60 million in capital and the possibility of up to $910 million in total payments if Incyte exercises its option. Additionally, Prelude announced the resignation of Jane Huang, M.D., as President and Chief Medical Officer, effective November 3, 2025, with Dr. Victor Sandor stepping in to provide strategic oversight.
The most recent analyst rating on (PRLD) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Prelude Therapeutics stock, see the PRLD Stock Forecast page.
Spark’s Take on PRLD Stock
According to Spark, TipRanks’ AI Analyst, PRLD is a Underperform.
Prelude Therapeutics faces significant financial hurdles due to ongoing losses and lack of revenue, which heavily impact its overall score. Technical analysis shows mixed short-term momentum, but long-term weakness persists. The valuation is challenged by a negative P/E ratio and lack of dividends. However, recent corporate developments, including promising clinical results and a solid cash runway, offer some positive aspects, albeit insufficient to offset the broader financial concerns.
To see Spark’s full report on PRLD stock, click here.
More about Prelude Therapeutics
Prelude Therapeutics is a clinical-stage precision oncology company focused on developing innovative medicines for cancer patients. Their pipeline includes highly selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, targeting clinically validated areas with transformative potential.
Average Trading Volume: 779,633
Technical Sentiment Signal: Buy
Current Market Cap: $225.2M
For a thorough assessment of PRLD stock, go to TipRanks’ Stock Analysis page.